Prolyl hydroxylase-3 is a novel renal cell carcinoma biomarker

Kwang Hyun Kim, Hyung Ho Lee, Young Eun Yoon, Joon Chae Na, Kyung Sup Kim, Woong Kyu Han

Research output: Contribution to journalArticle

Abstract

Purpose: The aim of this study was to determine the suitability of serum prolyl hydroxylase-3 (PHD3) as a diagnostic or monitoring biomarker of renal cell carcinoma (RCC). Materials and Methods: Between October 2013 and March 2015, we prospectively recruited study participants. The RCC group consisted of 56 patients who underwent radical or partial nephrectomy. The control group included 56 healthy kidney donors and 13 patients with benign renal masses. Blood from the RCC patients was sampled prior to surgery and again 1 and 3 months after the operation. Serum PHD3 levels were measured via enzyme-linked immunosorbent assay and compared between RCC patients and controls. Results: RCC patients had higher serum PHD3 levels than controls (0.79±0.17 ng/mL vs. 0.73±0.09 ng/mL, p=0.023), with an area under curve (AUC) of 0.668. With a cutoff value of 0.761 ng/ml, the sensitivity, specificity, positive predictive value, and negative predictive value were 66.1%, 68.1%, 28.8%, and 37.3%, respectively. No significant difference in PHD3 level was observed between healthy kidney donors and patients with benign renal masses. The predictive performance of PHD3 was improved in subgroup analyses of RCC patients with a tumor size >2 cm (n=40) or clear-cell histology (n=44), with AUCs of 0.709 and 0.688, respectively. Among 37 patients with PHD3 levels greater than the cutoff value of 0.761 ng/mL, the postoperative PHD3 levels at 1 and 3 months were significantly lower than the preoperative PHD3 levels (both p<0.001). Conclusions: Serum PHD3 represents a novel RCC biomarker that shows acceptable diagnostic performance.

Original languageEnglish
Pages (from-to)425-431
Number of pages7
JournalInvestigative and clinical urology
Volume60
Issue number6
DOIs
Publication statusPublished - 2019 Nov

Fingerprint

Renal Cell Carcinoma
Biomarkers
Kidney
Serum
Area Under Curve
Tissue Donors
2-oxoglutarate 3-dioxygenase proline
Nephrectomy
Blood Cells
Histology
Enzyme-Linked Immunosorbent Assay
Sensitivity and Specificity
Control Groups

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

Kim, Kwang Hyun ; Lee, Hyung Ho ; Yoon, Young Eun ; Na, Joon Chae ; Kim, Kyung Sup ; Han, Woong Kyu. / Prolyl hydroxylase-3 is a novel renal cell carcinoma biomarker. In: Investigative and clinical urology. 2019 ; Vol. 60, No. 6. pp. 425-431.
@article{e27ff635dc484238b663c2f7fa340e09,
title = "Prolyl hydroxylase-3 is a novel renal cell carcinoma biomarker",
abstract = "Purpose: The aim of this study was to determine the suitability of serum prolyl hydroxylase-3 (PHD3) as a diagnostic or monitoring biomarker of renal cell carcinoma (RCC). Materials and Methods: Between October 2013 and March 2015, we prospectively recruited study participants. The RCC group consisted of 56 patients who underwent radical or partial nephrectomy. The control group included 56 healthy kidney donors and 13 patients with benign renal masses. Blood from the RCC patients was sampled prior to surgery and again 1 and 3 months after the operation. Serum PHD3 levels were measured via enzyme-linked immunosorbent assay and compared between RCC patients and controls. Results: RCC patients had higher serum PHD3 levels than controls (0.79±0.17 ng/mL vs. 0.73±0.09 ng/mL, p=0.023), with an area under curve (AUC) of 0.668. With a cutoff value of 0.761 ng/ml, the sensitivity, specificity, positive predictive value, and negative predictive value were 66.1{\%}, 68.1{\%}, 28.8{\%}, and 37.3{\%}, respectively. No significant difference in PHD3 level was observed between healthy kidney donors and patients with benign renal masses. The predictive performance of PHD3 was improved in subgroup analyses of RCC patients with a tumor size >2 cm (n=40) or clear-cell histology (n=44), with AUCs of 0.709 and 0.688, respectively. Among 37 patients with PHD3 levels greater than the cutoff value of 0.761 ng/mL, the postoperative PHD3 levels at 1 and 3 months were significantly lower than the preoperative PHD3 levels (both p<0.001). Conclusions: Serum PHD3 represents a novel RCC biomarker that shows acceptable diagnostic performance.",
author = "Kim, {Kwang Hyun} and Lee, {Hyung Ho} and Yoon, {Young Eun} and Na, {Joon Chae} and Kim, {Kyung Sup} and Han, {Woong Kyu}",
year = "2019",
month = "11",
doi = "10.4111/icu.2019.60.6.425",
language = "English",
volume = "60",
pages = "425--431",
journal = "Investigative and Clinical Urology",
issn = "2466-0493",
publisher = "Korean Urological Association",
number = "6",

}

Prolyl hydroxylase-3 is a novel renal cell carcinoma biomarker. / Kim, Kwang Hyun; Lee, Hyung Ho; Yoon, Young Eun; Na, Joon Chae; Kim, Kyung Sup; Han, Woong Kyu.

In: Investigative and clinical urology, Vol. 60, No. 6, 11.2019, p. 425-431.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prolyl hydroxylase-3 is a novel renal cell carcinoma biomarker

AU - Kim, Kwang Hyun

AU - Lee, Hyung Ho

AU - Yoon, Young Eun

AU - Na, Joon Chae

AU - Kim, Kyung Sup

AU - Han, Woong Kyu

PY - 2019/11

Y1 - 2019/11

N2 - Purpose: The aim of this study was to determine the suitability of serum prolyl hydroxylase-3 (PHD3) as a diagnostic or monitoring biomarker of renal cell carcinoma (RCC). Materials and Methods: Between October 2013 and March 2015, we prospectively recruited study participants. The RCC group consisted of 56 patients who underwent radical or partial nephrectomy. The control group included 56 healthy kidney donors and 13 patients with benign renal masses. Blood from the RCC patients was sampled prior to surgery and again 1 and 3 months after the operation. Serum PHD3 levels were measured via enzyme-linked immunosorbent assay and compared between RCC patients and controls. Results: RCC patients had higher serum PHD3 levels than controls (0.79±0.17 ng/mL vs. 0.73±0.09 ng/mL, p=0.023), with an area under curve (AUC) of 0.668. With a cutoff value of 0.761 ng/ml, the sensitivity, specificity, positive predictive value, and negative predictive value were 66.1%, 68.1%, 28.8%, and 37.3%, respectively. No significant difference in PHD3 level was observed between healthy kidney donors and patients with benign renal masses. The predictive performance of PHD3 was improved in subgroup analyses of RCC patients with a tumor size >2 cm (n=40) or clear-cell histology (n=44), with AUCs of 0.709 and 0.688, respectively. Among 37 patients with PHD3 levels greater than the cutoff value of 0.761 ng/mL, the postoperative PHD3 levels at 1 and 3 months were significantly lower than the preoperative PHD3 levels (both p<0.001). Conclusions: Serum PHD3 represents a novel RCC biomarker that shows acceptable diagnostic performance.

AB - Purpose: The aim of this study was to determine the suitability of serum prolyl hydroxylase-3 (PHD3) as a diagnostic or monitoring biomarker of renal cell carcinoma (RCC). Materials and Methods: Between October 2013 and March 2015, we prospectively recruited study participants. The RCC group consisted of 56 patients who underwent radical or partial nephrectomy. The control group included 56 healthy kidney donors and 13 patients with benign renal masses. Blood from the RCC patients was sampled prior to surgery and again 1 and 3 months after the operation. Serum PHD3 levels were measured via enzyme-linked immunosorbent assay and compared between RCC patients and controls. Results: RCC patients had higher serum PHD3 levels than controls (0.79±0.17 ng/mL vs. 0.73±0.09 ng/mL, p=0.023), with an area under curve (AUC) of 0.668. With a cutoff value of 0.761 ng/ml, the sensitivity, specificity, positive predictive value, and negative predictive value were 66.1%, 68.1%, 28.8%, and 37.3%, respectively. No significant difference in PHD3 level was observed between healthy kidney donors and patients with benign renal masses. The predictive performance of PHD3 was improved in subgroup analyses of RCC patients with a tumor size >2 cm (n=40) or clear-cell histology (n=44), with AUCs of 0.709 and 0.688, respectively. Among 37 patients with PHD3 levels greater than the cutoff value of 0.761 ng/mL, the postoperative PHD3 levels at 1 and 3 months were significantly lower than the preoperative PHD3 levels (both p<0.001). Conclusions: Serum PHD3 represents a novel RCC biomarker that shows acceptable diagnostic performance.

UR - http://www.scopus.com/inward/record.url?scp=85074696316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074696316&partnerID=8YFLogxK

U2 - 10.4111/icu.2019.60.6.425

DO - 10.4111/icu.2019.60.6.425

M3 - Article

C2 - 31692952

AN - SCOPUS:85074696316

VL - 60

SP - 425

EP - 431

JO - Investigative and Clinical Urology

JF - Investigative and Clinical Urology

SN - 2466-0493

IS - 6

ER -